Immunology and Microbiology
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus 1
98%
Human Immunodeficiency Virus 2
40%
Genetic Variability
27%
Cladistics
24%
Neutralizing Antibody
24%
Virus
22%
Dynamics
20%
Glycoprotein
19%
Drug Resistance
18%
Viral Load
16%
Antibody Response
15%
Blood Plasma
13%
Phylogeny
12%
Antibodies
11%
Epitope
10%
Mycobacterium Tuberculosis
10%
Peptides
10%
CXCR4
8%
Prevalence
8%
Env (Gene)
8%
HIV/AIDS
8%
Population Structure
7%
Binding Antibody
7%
Hepatitis C Virus
7%
Lineages
7%
Disease Burden
7%
Drug Sensitivity
6%
CD4
6%
Immunoglobulin A
6%
Single-Domain Antibody
6%
Vaccinia Virus
5%
Neutralization
5%
Evolution
5%
Medicine and Dentistry
Global Disease Burden
74%
Human Immunodeficiency Virus
41%
Diseases
25%
Life Expectancy
23%
Drug Resistance
18%
Mortality Rate
17%
Disability Adjusted Life Years
15%
Genetic Variability
15%
Prevalence
14%
Health Care
12%
Systematic Review
11%
Public Health
8%
Mental Capacity
8%
Reverse-Transcriptase Inhibitor
8%
COVID-19
8%
Low and Middle Income Countries
7%
HIV/AIDS
7%
Non Communicable Disease
7%
Meta-Analysis
7%
Human Immunodeficiency Virus 1
7%
Highly Active Antiretroviral Therapy
7%
Geographic Mapping
7%
Mycobacterium Tuberculosis
7%
Demography
7%
Respiratory Tract Infection
6%
Health System
6%
Diarrhea
6%
Infection
5%
Resistance Mutation
5%
Newborn Disease
5%
Human Immunodeficiency Virus 2
5%
Population Structure
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Ischemic Heart Disease
5%
Population Growth
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
71%
Global Disease Burden
46%
Drug Resistance
27%
Diseases
21%
Anti-Human Immunodeficiency Virus
19%
Antimicrobial Agent
17%
Prevalence
16%
Lactam
10%
RNA Directed DNA Polymerase Inhibitor
10%
Infection
9%
Human Immunodeficiency Virus 2
8%
Human Immunodeficiency Virus Fusion Inhibitor
7%
Hepatitis C
7%
Drug Carrier
7%
Mycobacterium Tuberculosis
7%
Human Immunodeficiency Virus 1
7%
Hepatitis B
7%
Polyethylene Glycol
7%
Nanoparticle
7%
Hepatitis C Virus
7%
Pharmacokinetics
7%
Fusion Inhibitor
7%
Non Communicable Disease
6%
Hepatitis B Virus
6%
Cohort Study
6%
Plasmodium
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Proteinase Inhibitor
5%
Antiplasmodial Activity
5%
Ethanol
5%
Life Expectancy
5%
Antiinfective Agent
5%
